Last updated: May 25, 2026
Which companies supply dopamine hydrochloride injection in D5W (plastic container) in the US?
Current supplier set for the specific presentation “dopamine hydrochloride in dextrose 5% in plastic container” is not determinable from the information provided.
A complete supplier map requires the exact FDA product label/strength, container size, and national drug code (NDC) entries (these presentations can differ by concentration, total volume, and container type, which changes the supplier list).
What NDCs exist for dopamine hydrochloride in dextrose 5% in plastic containers?
No NDC-indexed listing can be produced from the information provided.
In practice, the same active ingredient “dopamine hydrochloride in D5W” may appear under multiple NDCs based on:
- different concentrations/strengths (mg/mL)
- different total volumes (e.g., 100 mL vs 250 mL)
- different container types (plastic vs glass)
- different labeling configurations (premix vs pharmacy bulk pack)
Without NDCs, a reliable enumerations of products and manufacturers is not possible.
How many suppliers can stock dopamine hydrochloride in D5W plastic (single-source concentration)?
Not computable from the information provided.
Supplier count depends on:
- whether the product is commercially marketed in the US
- whether availability is driven by CDMO fill-finish versus label-holder distribution
- whether shortages or discontinuations have narrowed the market
What is the Orange Book status of dopamine hydrochloride in dextrose 5% (plastic)?
Not determinable from the information provided.
Orange Book status depends on:
- the specific drug product entry (by NDC)
- the approval pathway and listed patents
- whether the product is authorized under a branded NDA/ANDA or a “listed drug” only
What generic entry risks exist for dopamine hydrochloride in D5W plastic?
Not determinable from the information provided.
Generic risk analysis requires:
- patent estate/patent expiration timing
- whether ANDA applicants target the same container/packaging and strength
- whether substitution is constrained by labeling or container interchangeability
Who are the manufacturer-of-record and fill-finish suppliers?
Not determinable from the information provided.
For injectable D5W admixtures, the manufacturing-of-record and the actual fill-finish site can differ. Supplier visibility typically comes from:
- FDA label and package insert
- listing in FDA drug databases
- packaging and lot number traceability
- manufacturing disclosures in regulatory filings
Which plastic container suppliers are used for dopamine hydrochloride in D5W?
Not determinable from the information provided.
Container supply for IV fluids varies by:
- plastic bag composition (e.g., EVA-based)
- overwrap and sterilization process
- compatibility constraints and leachables
- bag size and film grade
A container-supplier list requires product-specific packaging disclosures or NDC-to-label mapping.
What procurement and lead-time constraints apply to dopamine hydrochloride premix in D5W?
Not determinable from the information provided.
Procurement constraints depend on:
- regional distribution of the exact NDC
- hospital contract coverage by GPO
- tier-1 substitutions permitted by pharmacy and purchasing
- historical shortage events for that presentation
What litigation or FDA enforcement affects dopamine hydrochloride D5W plastic?
Not determinable from the information provided.
Legal and enforcement impact is presentation-specific and requires:
- FDA inspections and enforcement reports for the approved drug product sites
- recalls tied to lot numbers for that NDC
- patent litigation connected to the specific product NDA/ANDA
Key takeaways
- A reliable supplier list for dopamine hydrochloride in dextrose 5% in plastic container cannot be produced without presentation-specific identifiers (at minimum: strength, volume, and NDC).
- Supplier mapping, Orange Book status, generic entry risk, and manufacturing-of-record analysis are NDC-level exercises and are not possible from the provided description alone.
FAQs
- Can dopamine hydrochloride in D5W be sourced from multiple NDCs with the same concentration?
- Do plastic container variations (bag size or film type) change substitution at the pharmacy level?
- How does an NDC-level change affect procurement contracts for dopamine hydrochloride premix?
- What data sources normally provide supplier-of-record for IV premix products?
- How are shortages tracked for specific injectable presentations in D5W with plastic bags?
References
No sources cited because no verifiable product identifiers or regulatory records were provided.
